PSI CRO will host a dynamic session on agentic AI in clinical trials, exploring its capabilities and potential. Sponsors, AI experts, and PSI CRO will discuss its role in tackling protocol complexity, improving efficiency, and meeting evolving regulatory demands. We will review current applications of agentic AI across protocol design, startup, enrollment, and data analysis, alongside future advances such as adaptive trials and semi-autonomous monitoring. A moderated debate will explore the real value of agentic AI, barriers to adoption, and what we expect to come next.
Tuesday, May 5, 09:00 - 09:45, room Kairo
| Name | Position | Institution |
|---|---|---|
| Kirill Soldatov | Head Process Improvement | PSI CRO |
PSI CRO is a global, full-service contract research organization known for on-time trial delivery; this key operational metric consistently exceeded 90% in 2025. PSI specializes in pivotal phase 2 and phase 3 trials in infectious diseases, oncology, hematology, GI, immunology, neuroscience, and other complex indications. Since 2010, PSI helped bring 50% of novel antibiotics to market.
In 2025, PSI celebrated its 30th year as the only fully independent and privately owned mid-sized CRO. The company employs over 3,200 professionals across 58 countries as of February 1, 2026. PSI’s global headquarters are in Zug, Switzerland.
